拓展肝细胞癌的免疫治疗蓝图。
Expanding the immunotherapy roadmap for hepatocellular carcinoma.
机构信息
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Division of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
出版信息
Cancer Cell. 2022 Mar 14;40(3):252-254. doi: 10.1016/j.ccell.2022.02.017.
Abstract
In a recent Lancet Oncology article, Yau et al. report the CheckMate 459 trial results. This is the first phase III trial comparing the single-agent anti-programmed death protein 1 (PD-1) therapy nivolumab to the tyrosine kinase inhibitor sorafenib for treatment-naive patients with advanced hepatocellular carcinoma.
摘要
在最近的《柳叶刀肿瘤学》杂志的一篇文章中，Yau 等人报告了 CheckMate 459 试验的结果。这是首个比较单药抗程序性死亡蛋白 1（PD-1）治疗药物纳武利尤单抗与酪氨酸激酶抑制剂索拉非尼治疗初治晚期肝细胞癌患者的 III 期临床试验。
相似文献
1
Expanding the immunotherapy roadmap for hepatocellular carcinoma.拓展肝细胞癌的免疫治疗蓝图。
Cancer Cell. 2022 Mar 14;40(3):252-254. doi: 10.1016/j.ccell.2022.02.017.
2
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.纳武利尤单抗对比索拉非尼用于治疗晚期肝细胞癌（CheckMate 459）：一项随机、多中心、开放标签、III 期临床试验。
Lancet Oncol. 2022 Jan;23(1):77-90. doi: 10.1016/S1470-2045(21)00604-5. Epub 2021 Dec 13.
3
Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib.纳武利尤单抗+伊匹木单抗用于索拉非尼治疗后 HCC 患者
Expert Rev Gastroenterol Hepatol. 2021 Jun;15(6):589-598. doi: 10.1080/17474124.2021.1899808. Epub 2021 Mar 19.
4
Nivolumab for the treatment of hepatocellular carcinoma.纳武利尤单抗治疗肝细胞癌。
Expert Rev Anticancer Ther. 2018 Dec;18(12):1169-1175. doi: 10.1080/14737140.2018.1535315. Epub 2018 Oct 22.
5
Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis.纳武利尤单抗治疗晚期肝细胞癌：索拉非尼经治亚洲人群队列分析。
J Hepatol. 2019 Sep;71(3):543-552. doi: 10.1016/j.jhep.2019.05.014. Epub 2019 Jun 7.
6
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.纳武利尤单抗治疗晚期肝细胞癌患者（CheckMate 040）：一项开放标签、非对照、1/2 期剂量递增和扩展试验。
Lancet. 2017 Jun 24;389(10088):2492-2502. doi: 10.1016/S0140-6736(17)31046-2. Epub 2017 Apr 20.
7
Prolonged response to Tyrosine Kinase Inhibitors followed by Immunotherapy in metastatic hepatocellular carcinoma: A rare case report.酪氨酸激酶抑制剂治疗后免疫治疗转移性肝细胞癌的长期反应：一例罕见病例报告。
J Cancer Res Ther. 2023 Jul-Sep;19(5):1457-1461. doi: 10.4103/jcrt.JCRT_1251_21.
8
[Clinical research progression of molecular-targeted drugs and PD-1 inhibitors for advanced hepatocellular carcinoma].[晚期肝细胞癌分子靶向药物与PD-1抑制剂的临床研究进展]
Zhonghua Zhong Liu Za Zhi. 2019 Jun 23;41(6):406-409. doi: 10.3760/cma.j.issn.0253-3766.2019.06.002.
9
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.CheckMate 040 队列 5：纳武利尤单抗治疗晚期肝细胞癌和 Child-Pugh B 级肝硬化患者的 I/II 期研究。
J Hepatol. 2021 Sep;75(3):600-609. doi: 10.1016/j.jhep.2021.04.047. Epub 2021 May 26.
10
PD-1 targeted immunotherapy for advanced hepatocellular carcinoma: current utilization and outcomes in the USA.PD-1 靶向免疫疗法治疗晚期肝细胞癌：美国的当前应用和结果。
Future Oncol. 2022 May;18(14):1691-1703. doi: 10.2217/fon-2021-1487. Epub 2022 Feb 17.
引用本文的文献
1
Deciphering the Multifaceted Immune Landscape of Unresectable Primary Liver Cancer to Predict Immunotherapy Response.解析不可切除原发性肝癌的多维度免疫格局以预测免疫治疗反应
Adv Sci (Weinh). 2024 Dec;11(47):e2309631. doi: 10.1002/advs.202309631. Epub 2024 Oct 28.
2
METTL3 and METTL14-mediated N-methyladenosine modification of SREBF2-AS1 facilitates hepatocellular carcinoma progression and sorafenib resistance through DNA demethylation of SREBF2.METTL3 和 METTL14 介导的 SREBF2-AS1 的 N6-甲基腺苷修饰通过 SREBF2 的 DNA 去甲基化促进肝细胞癌进展和索拉非尼耐药。
Sci Rep. 2024 Mar 14;14(1):6155. doi: 10.1038/s41598-024-55932-7.
3
N-Methyladenosine-Modified LEAWBIH Drives Hepatocellular Carcinoma Progression through Epigenetically Activating Wnt/β-Catenin Signaling.N-甲基腺苷修饰的LEAWBIH通过表观遗传激活Wnt/β-连环蛋白信号通路驱动肝细胞癌进展。
J Hepatocell Carcinoma. 2023 Nov 6;10:1991-2007. doi: 10.2147/JHC.S433070. eCollection 2023.
4
mA modification of AC026356.1 facilitates hepatocellular carcinoma progression by regulating the IGF2BP1-IL11 axis.mA 对 AC026356.1 的修饰通过调节 IGF2BP1-IL11 轴促进肝癌进展。
Sci Rep. 2023 Nov 5;13(1):19124. doi: 10.1038/s41598-023-45449-w.
5
N-Methyladenosine-Modified ATP8B1-AS1 Exerts Oncogenic Roles in Hepatocellular Carcinoma via Epigenetically Activating MYC.N-甲基腺苷修饰的ATP8B1-AS1通过表观遗传激活MYC在肝细胞癌中发挥致癌作用。
J Hepatocell Carcinoma. 2023 Sep 6;10:1479-1495. doi: 10.2147/JHC.S415318. eCollection 2023.
6
Factors associated with the survival outcomes of patients with untreated hepatocellular carcinoma: An analysis of nationwide data.未经治疗的肝细胞癌患者生存结局的相关因素：一项全国性数据分析
Front Oncol. 2023 Mar 22;13:1142661. doi: 10.3389/fonc.2023.1142661. eCollection 2023.
7
First-line treatments for advanced hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis in China and the United States.晚期肝细胞癌的一线治疗：中国和美国的网络荟萃分析及成本效益分析
Therap Adv Gastroenterol. 2022 Dec 9;15:17562848221140662. doi: 10.1177/17562848221140662. eCollection 2022.
8
Blood-based biomarkers for immune-based therapy in advanced HCC: Promising but a long way to go.晚期肝癌基于免疫治疗的血液生物标志物：前景光明但仍任重道远。
Front Oncol. 2022 Oct 31;12:1028728. doi: 10.3389/fonc.2022.1028728. eCollection 2022.
本文引用的文献
1
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.纳武利尤单抗对比索拉非尼用于治疗晚期肝细胞癌（CheckMate 459）：一项随机、多中心、开放标签、III 期临床试验。
Lancet Oncol. 2022 Jan;23(1):77-90. doi: 10.1016/S1470-2045(21)00604-5. Epub 2021 Dec 13.
2
Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity.新辅助卡博替尼和纳武单抗将局部晚期肝癌转化为可切除疾病并增强抗肿瘤免疫力。
Nat Cancer. 2021 Sep;2(9):891-903. doi: 10.1038/s43018-021-00234-4. Epub 2021 Jul 29.
3
Advances in immunotherapy for hepatocellular carcinoma.肝细胞癌的免疫治疗进展。
Nat Rev Gastroenterol Hepatol. 2021 Aug;18(8):525-543. doi: 10.1038/s41575-021-00438-0. Epub 2021 Apr 13.
4
Hepatocellular carcinoma.肝细胞癌。
Nat Rev Dis Primers. 2021 Jan 21;7(1):6. doi: 10.1038/s41572-020-00240-3.
5
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
6
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.帕博利珠单抗作为 KEYNOTE-240 中晚期肝细胞癌二线治疗的疗效：一项随机、双盲、III 期试验。
J Clin Oncol. 2020 Jan 20;38(3):193-202. doi: 10.1200/JCO.19.01307. Epub 2019 Dec 2.
7
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.估算 2018 年全球癌症发病率和死亡率：GLOBOCAN 来源和方法。
Int J Cancer. 2019 Apr 15;144(8):1941-1953. doi: 10.1002/ijc.31937. Epub 2018 Dec 6.
8
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.纳武利尤单抗治疗晚期肝细胞癌患者（CheckMate 040）：一项开放标签、非对照、1/2 期剂量递增和扩展试验。
Lancet. 2017 Jun 24;389(10088):2492-2502. doi: 10.1016/S0140-6736(17)31046-2. Epub 2017 Apr 20.
9
Sorafenib in advanced hepatocellular carcinoma.索拉非尼用于晚期肝细胞癌
N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.
Zotero 插件